Ignite Creation Date:
2024-10-26 @ 3:35 PM
Last Modification Date:
2024-10-26 @ 3:35 PM
Study NCT ID:
NCT06504082
Status:
COMPLETED
Last Update Posted:
None
First Post:
2024-06-30
Brief Title:
Comparison of the Effectiveness of Single-Dose Methotrexate Protocol With Letrozole Single-Dose Methotrexate in the Medical Treatment of Patients Diagnosed With Ectopic Pregnancy
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Comparison of the Effectiveness of Single-Dose Methotrexate Protocol With Letrozole Single-Dose Methotrexate in the Medical Treatment of Patients Diagnosed With Ectopic Pregnancy
Status:
COMPLETED
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The objective of the study is to compare the effectiveness of single-dose methotrexate and letrozole single-dose methotrexate in treating ectopic pregnancy focusing on treatment success changes in ß-hCG levels hemogram and biochemical markers surgical intervention due to rupture fertility preservation and reduction of maternal morbidity mortality and healthcare costs This is a prospective study conducted on 60 ectopic pregnancy patients at Van Yuzuncu Yil University from June 2021 to September 2022 Thirty patients received single-dose methotrexate while the other thirty received letrozole single-dose methotrexate Inclusion criteria were ß-hCG 5000 mIUmL ectopic mass 3-4 cm no persistent abdominal pain no fetal cardiac activity and no contraindications to the treatments Outcomes measured included treatment success blood parameter changes and the need for surgical intervention
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None